Long-term efficacy and safety analysis of vedolizumab in the treatment of moderate to severe ulcerative colitis: a single-center retrospective observational study
10.3760/cma.j.cn101480-20231027-00037
- VernacularTitle:维得利珠单克隆抗体治疗中重度溃疡性结肠炎的长期疗效及安全性的单中心回顾性观察研究
- Author:
Haitao SHI
1
;
Sumei SHA
1
;
Qiang LI
1
;
Qing FAN
1
;
Yan WANG
1
;
Xin LIU
1
Author Information
1. 西安交通大学第二附属医院消化内科，西安 710004
- Publication Type:Journal Article
- Keywords:
Ulcerative colitis;
Vedolizumab;
Long-term efficacy;
Safety
- From:
Chinese Journal of Inflammatory Bowel Diseases
2024;08(4):274-277
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the long-term efficacy and safety of vedolizumab (VDZ) in the treatment of patients with moderate to severe ulcerative colitis (UC) .Methods:Clinical data of patients with moderate to severe active UC receiving VDZ treatment for more than 52 weeks at the Department of Gastroenterology of the Second Affiliated Hospital of Xi′an Jiaotong University from February 2021 to April 2023 were retrospectively collected. The observation indexes were clinical response rate, clinical remission rate, endoscopic mucosal healing rate and adverse events after 52 weeks of treatment.Results:A total of 21 patients with moderate to severe UC with complete data were included in this study, including 17 moderate and 4 severe patients with a mean age of (44.2±14.3) years, 17 males and 4 females, and a disease duration of 60 (36, 103) months. The clinical response rate, clinical remission rate, and endoscopic mucosal healing rate at week 52 were 85.7% (18/21) , 76.2% (16/21) and 71.4% (15/21) respectively. Of the 21 patients, 2 (9.5%) had increased transaminases, 5 (23.8%) had clostridium difficile infection and 1 (4.8%) had intestinal EBV infection, with no other adverse effects. Conclusion:VDZ has favorable long-term efficacy and safety in patients with moderate to severe active UC.
